MedTrace Logo

Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types

NCT03012620 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 334

Last updated 2024-02-28

No results posted yet for this study

Summary

This is a Phase 2, non-randomised, open-label, multicentric study to investigate the efficacy and safety of pembrolizumab monotherapy in 7 cohorts of patients with specific rare cancers who have unresectable locally advanced or metastatic disease, which is resistant or refractory to standard therapy, or for which standard therapy does not exist, or is not considered appropriate, and for which no other experimental treatment options are available, in order to identify subsets of patients that may benefit from treatment

Conditions

  • Sarcoma
  • Ovarian Neoplasm
  • Central Nervous System Neoplasm
  • Thyroid Neoplasm
  • Carcinoma, Neuroendocrine
  • Neoplasms, Germ Cell and Embryonal
  • NK/T-cell Lymphoma

Interventions

DRUG

Pembrolizumab

Treatment

Sponsors & Collaborators

  • National Cancer Institute, France

    collaborator OTHER_GOV

  • Ligue contre le cancer, France

    collaborator OTHER

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • UNICANCER

    lead OTHER

Principal Investigators

  • Christophe Massard, MD · Gustave Roussy Cancer Campus

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-05
Primary Completion
2022-12-26
Completion
2023-12-14

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03012620 on ClinicalTrials.gov